HNSBF - Hansa Biopharma provides Q1 update
2023-04-20 03:42:05 ET
-
Hansa Biopharma ( OTCPK:HNSBF ) expects t otal Q1 revenue of SEK24.2M including SEK14.3M in product sales and SEK9.9M in revenue recognition mainly under the agreement with Sarepta.
- Appointed Matthew Shaulis as Chief Commercial Officer and U.S. President of Hansa Biopharma.
- Enrollment in phase 2 study of imlifidase in Guillain-Barré Syndrome (GBS) completed.
- Cash and short-term investments at ~SEK1.29B.
For further details see:
Hansa Biopharma provides Q1 update